symptom relief. The patient remained enrolled in his PhD program but kept putting off his dissertation. Twenty-seven months into PEPP, he began a trial of clozapine.
At baseline cognitive assessment following entry into PEPP, the patient scored at or above average on measures of intellectual functioning, working memory, immediate and delayed auditory memory, delayed visual memory, and mental flexibility. Weakness (that is, a score 1 or more standard deviations below average) was demonstrated in immediate visual memory, concept formation, attention, and processing speed. The patient was not willing or able to tolerate the demands of testing again until 41 months after entering the program. At that time, he had been taking clozapine 400 mg daily for approximately 14 months. He showed significant improvement in positive and negative symptoms of psychosis. Significant gains in concept formation and attention were seen. Most notably, the patient demonstrated an improvement in speeded information processing, rising from over 2 standard deviations below average to 0.5 standard deviations below average (a gain of 31 points). Although he did not complete his PhD, he is now employed full-time in his field of study.
Discussion
The gain in processing speed following clozapine treatment was far beyond that reported in other studies (1-5), significantly greater than gains in other areas (suggesting differential impact), and not explained by practice effects. There were no changes in other cognitive domains. Since persistent clinical improvement and medication adherence was noted only after he started taking clozapine, the likelihood of cognitive gains predating clozapine is minimal.
Cognitive data from our centre involving a large sample of first-episode psychosis patients treated with novel antipsychotics (primarily risperidone) do not demonstrate the same degree of improvement in processing speed. This domain, in fact, remains an area of relative weakness, despite gains in other areas (8) . Symptom reduction is also not likely to explain this gain. Reports on the relation between cognition and symptoms have been inconsistent in the literature and are often weak, at best (9-11).
Our results confirm that clozapine treatment effectively enhances neurocognitive function and suggest that significant gains are possible, particularly in the area of processing speed. This effect was demonstrated after an extended period of unsuccessfully treated illness; the reported case supports this medication's benefit in stabilizing not only psychotic symptoms but also cognitive difficulties-even more than 3 years after the emergence of what appeared to be a treatment-resistant psychosis. This case demonstrates the need to consider introducing clozapine early, as well as the benefits of not waiting until several trials of other antipsychotics have been undertaken.
Problems With Crystallizing Phenomenology and Nosology in Adolescent Psychiatry

Dear Editor:
Debate over the DSM-IV criteria for child and adolescent disorders continues, focusing on developmental modifications to symptom clusters such as bipolar disorder and posttraumatic stress disorder (PTSD) and their expression in children and adolescents (1, 2) . Findings from a recent study on PTSD showed that absence of the triad does not indicate a lack of posttraumatic stress problems; rather, such absence may be owing to developmental differences in symptom expression. As such, current diagnostic criteria may not be appropriate for children (2) . Similarly, a study of major depression and dysthymia included pathological behaviour such as disobedience, which was found to be quite frequent in adolescents with dysthymia (3). Even though child or adolescent symptomatology may not fit the criteria for a diagnosis, there can be significant impairment, which is important for nosology and prognosis (4) . We report on 3 cases wherein symptom description and expression were ambiguous as a function of verbal expression, intelligence, and age-related psychosocial stresses.
Case Report 1: Depression-Growing Pain or True Morbidity?
A 16-year-old boy was admitted for acute suicidal risk after his third appointment with a psychiatrist. He first presented with symptoms of depression and met the criteria for major depressive disorder (MDD). He was given a selective serotonin reuptake inhibitor (SSRI) and weekly appointments. After a night on the ward, the patient showed dramatic improvement in mood, sleep, appetite, and energy. Medication was discontinued and he remained euthymic. He had significant learned helplessness attributable to an underlying learning disorder. Further inquiry revealed an amorous crisis as the main precipitator. The patient was discharged with a diagnosis of situational reaction.
Case Report 2: Psychosis or Hypomania?
A 17-year-old boy of limited intellectual and cognitive functioning was escorted by police and admitted involuntarily for insomnia and acute onset of nonstop activity lasting 72 hours. His maternal family history was positive for schizoaffective disorder. He was very suspicious on the ward, refusing ward food and isolating himself from others. He had no insight regarding his mental state and was noncompliant with medication. A drug screen was negative, and he had no neurological abnormalities. He was granted appeal against his admission and left 4 days later with a discharge diagnosis of queried bipolar affective disorder. He was readmitted 7 days later for psychiatric assessment and observation over 14 days. He had periods of immobility, agitation, and extreme negativism that were consistent with catatonia. He also had frank paranoid delusions and ideas of reference. Administration of zuclopenthixol acetate (50 mg) led to amelioration of symptoms, but not to their previous discharge level. The patient's discharge diagnosis was changed to schizophrenia, catatonic type. He was readmitted again 2 weeks later with a similar presentation. This time, he was transferred to a longerstay ward and put on depot neuroleptic owing to ongoing noncompliance.
Case Report 3: PTSD or Schizophrenia?
A 16-year-old girl with a history of sexual and physical abuse presented with periods of bizarre behaviour, auditory hallucinations, and persecutory delusions. At age 14 years, she had been diagnosed with PTSD attributable to chronic abuse; she did not respond to SSRI treatment. Previously, at age 12 years, she had been diagnosed with Asperger's disorder. Observation and assessment over a 3-week period showed bizarre delusions with incongruent affect, third-person hallucinations, thought disorder, and severely impaired functioning. Neuroleptic medication provided mild symptom relief, but her psychotic symptoms remained for 8 months. Her diagnosis was changed to schizophrenia, disorganized type.
These cases demonstrate that a disorder tends to evolve over time as the brain develops, before crystallizating into an operational diagnostic entity. Patients who are behaviourally and emotionally immature may not fully meet existing diagnostic criteria, because these often fail to take developmental stage into account (5) . In Case Report 1, the patient met criteria for MDD at his first consultation. However an adolescent's first breakup can have a highly significant impact on symptom presentation. Further, the time period required by the DSM-IV may be inadequate for an adolescent. In Case Report 2, the patient's extreme hyperactivity, disrespectful demeanour, and refusal to comply led to his behaviour being described as hypomanic, despite the absence of elevated mood and affect. Structured observation and assessment over time uncovered the underlying psychopathology and phenomenology. Note that catatonic symptoms are uncommon among adolescents. In Case Report 3, the patient's diagnosis of Asperger's disorder may have been a description of premorbidity to her later schizophrenic illness. The confusion arose from her known history of abuse; her presenting symptoms were attributed to dissociative phenomena rather than to positive symptoms of psychosis. The full presentation of schizophrenia can require the passage of 2 years to crystallize.
Note
These cases were previously presented as a poster at the World Psychiatric Association Symposium; June 2003; Vienna.
